Šutić Maja, Vukić Ana, Baranašić Jurica, Försti Asta, Džubur Feđa, Samaržija Miroslav, Jakopović Marko, Brčić Luka, Knežević Jelena
Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia.
Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany.
J Pers Med. 2021 Oct 27;11(11):1102. doi: 10.3390/jpm11111102.
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the "one-fits-all" paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer.
肺癌是全球癌症相关死亡的主要原因。尽管通过对高危人群进行筛查来早期发现肺癌的努力不断增加，但大多数肺癌患者仍在晚期被诊断出来。在过去十年中，肺癌的治疗有了显著改善，不再基于“一刀切”的模式或非小细胞肺癌与小细胞肺癌的一般组织学分类。靶向治疗和免疫治疗等新出现的选择已将肺癌的治疗转向更个性化的治疗方法，显著影响了该疾病的临床病程和结局。分子生物标志物已成为疾病预后和治疗反应预测的有价值工具。在本综述中，我们讨论了从诊断到预后在肺肿瘤临床管理中使用的相关生物标志物。我们还讨论了有前景的新生物标志物，重点关注作为最常见肺癌类型的非小细胞肺癌。
